Role of endogenous GLP-1 and its agonists in Osteopenia and osteoporosis: But we little know until tried

Current Diabetes Reviews

Volumn 10, Issue 1, 2014, Pages 43-47

  Papazafiropoulou, Athanasia ^a   Papanas, Nikolaos ^b   Pappas, Stavros ^a   Maltezos, Efstratios ^b  

^a GENERAL HOSPITAL OF NIKEA   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Bone metabolism; Fractures; GLP 1; Incretins; Type 2 diabetes mellitus

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST;

ARTICLE; BONE METABOLISM; BONE TURNOVER; EMBASE; EXPERIMENTAL STUDY; HUMAN; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

BONE AND BONES; BONE DISEASES, METABOLIC; CALCITONIN; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; OSTEOPOROSIS; PEPTIDES; RECEPTORS, GLUCAGON; TREATMENT OUTCOME; VENOMS;

EID: 84897456623     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399810666140217114848     Document Type: Article

References (28)

1. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166: 495-505.
2. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008; 31: 845-851.
3. Nicodemus KK, Folsom AR; Iowa Women's Health Study. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001; 24: 1192-1197.
4. Benvenuti S, Cellai I, Luciani P, et al. Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesen-chymal stem cells. J Endocrinol Invest 2007; 30: RC26-RC30.
5. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 2006; 91: 3404-3410.
6. Gupta V. Pleiotropic effects of incretins. Indian J Endocrinol Me-tab 2012; 16 Suppl 1: S47-S56.
7. Asmar M, Holst JJ. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances. Curr Opin Endocrinol Diabetes Obes 2010; 17: 57-62.
8. Irwin N, Gault V, Flatt PR. Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease? Expert Opin Investig Drugs 2010; 19: 1039-1048.
9. Nuche-Berenguer B, Moreno P, Esbrit P, et al. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int 2009; 84: 453-4561.
10. Antonopoulou M, Bahtiyar G, Banerji MA, Sacerdote AS. Diabetes and bone health. Maturitas 2013 Apr 26. [Epub ahead of print]
11. Bollag RJ, Zhong Q, Ding KH, et al. Glucose-dependent insuli- notropic peptide is an integrative hormone with osteotropic effects. Mol Cell Endocrinol 2001; 177: 35-41.
12. Xie D, Zhong Q, Ding KH, et al. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone 2007; 40: 1352-1360.
13. Ding KH, Shi XM, Zhong Q, et al. Impact of glucose-dependent insulinotropic peptide on age-induced bone loss. J Bone Miner Res 2008; 23: 536-543.
14. Nuche-Berenguer B, Moreno P, Portal-Nuñez S, Dapía S, Esbrit P, Villanueva-Peñacarrillo ML. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept 2010; 159: 61-66.
15. Nuche-Berenguer B, Lozano D, Gutiérrez-Rojas I, et al. GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia. J Endocrinol 2011; 209: 203-210.
16. Ma X, Meng J, Jia M, et al. Exendin-4, a GLP-1 receptor agonist, prevents osteopnia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. J Bone Miner Res 2013 Feb 20. [Epub ahead of print]
17. Kim JY, Lee SK, Jo KJ, et al. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes. Life Sci 2013; 92: 533-540.
18. Pérez-Castrillón JL, Riancho JA, de Luis D, et al. The deleterious effect of bariatric surgery on cortical and trabecular bone density in the femurs of non-obese, type 2 diabetic Goto-Kakizaki rats. Obes Surg 2012; 22: 1755-1760.
19. Henriksen DB, Alexandersen P, Bjarnason NH, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003; 18: 2180-2189.
20. Bunck MC, Eliasson B, Cornér A, et al. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 374-377.
21. Henriksen DB, Alexandersen P, Hartmann B, et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 2009; 45: 833-842.
22. Gottschalck IB, Jeppesen PB, Holst JJ, Henriksen DB. Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract. Scand J Gastroen-terol 2008; 43: 929-937.
23. Nuche-Berenguer B, Portal-Núñez S, Moreno P, et al. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J Cell Physiol 2010; 225: 585-592.
24. Pacheco-Pantoja EL, Ranganath LR, Gallagher JA, Wilson PJ, Fraser WD. Receptors and effects of gut hormones in three os-teoblastic cell lines. BMC Physiol 2011; 11: 12.
25. Yamada C, Yamada Y, Tsukiyama K, et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 2008; 149: 574-579.
26. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hy-perglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
27. N. Papanas, E. Maltezos. Antidiabetic treatment: Though lovers be lost, love shall not. World J Diabetes 2012; 3: 158-160.
28. st October 2013.